drugset / Trial / NCT01150630

Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer

NCT01150630 ↗

Phase 2 Completed 98 enrolled IRCCS San Raffaele
RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, epirubicin hydrochloride, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine hydrochloride, with or without cisplatin, epirubicin hydrochloride, and capecitabine before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these drugs after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase II/III trial is studying how well gemcitabine hydrochloride, with or without cisplatin, epirubicin hydrochloride, and capecitabine, works when given before and/or after surgery in treating patients with stage I or stage II pancreatic cancer that can be removed by surgery.

Timeline

Start
2010-05
Primary completion
2017-04
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1250 mg/m2 Oral
Subject Cisplatin Other / unclassified 30 mg/m2 Intravenous
Subject Epirubicin Small molecule 30 mg/m2 Intravenous
Subject Gemcitabine Small molecule 800 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous